Aterm Pregnant Women with Human Immunodeficiency Virus Infection Which Receive Antiretroviral Therapy Combination of Nucleoside Analogue Reverse Transcriptase Inhibitor as A Risk Factor of High Expression of Apoptosis Including Factors



Abstract Views
498

Downloads
297

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Apr 9, 2022
Published May 17, 2022
10.24018/ejmed.2022.4.3.1325

Abstract viewed = 498 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

Aim: To determine whether term pregnant women with human immunodeficiency virus infection who received antiretroviral therapy had high apoptosis inducing factor expression in the placenta.

Methods: This cross-sectional analytical study was conducted at Sanglah General Hospital, Denpasar, and educational network hospitals. Subjects collected were termed pregnant women with HIV (+) who received antiretroviral therapy (ART) 6 months as a risk group and pregnant women with HIV (-) as a non-risk group. AIF expression was assessed by immunohistochemical examination of placental tissue. The AIF expression cut-off value was determined by constructing a receiver operating characteristics (ROC) curve. The chi-square test assessed the difference in proportion by displaying the prevalence ratio (RP) results. The significance of this study was p<0.05.

Results: 40 pregnant women were included in the risk and no-risk groups. There was no difference in age, gestational age, parity and BMI in the two groups. The mean AIF expression was significantly higher in the group with HIV (+) (162±52.5) ​​than HIV (-) (126.75±61.4), p-value = 0.003. The cut-off value of AIF expression was 112.50, with a sensitivity of 80% and a specificity of 45%. After classification, a significantly higher proportion of AIF expression was found in the HIV (+) group (42.5%) than in the HIV (-) group (27.5%) with p=0.038. Pregnant women with HIV (+) and receiving antiretroviral therapy for six months had a 4.6 times higher chance of having a high AIF prevalence than pregnant women who were not infected with HIV (RP=4.63; 95% CI=1.023 – 21.004).

Conclusion: Term pregnant women with HIV infection who received antiretroviral therapy had high AIF expression in the placenta.

Keywords: AIF expression, antiretroviral therapy, human immunodeficiency virus, term pregnancy

Downloads

Download data is not yet available.

References

  1. Stover J, Glaubius R, Teng Y, et al. Modeling the epidemiological impact of the UNAIDS 2025 targets to end AIDS as a public health threat by 2030. PLoS Med. 2021; 18(10): e1003831.
    DOI  |   Google Scholar
  2. Abrams EJ, Mofenson LM, Pozniak A, Lockman S, Colbers A, Belew Y, et al. Enhanced and Timely Investigation of ARVs for Use in Pregnant Women. J Acquir Immune Defic Syndr. 2021; 86(5): 607-615.
    DOI  |   Google Scholar
  3. Badru O, Dairo MD, Oladokun RE. Quality of Life of HIV Infected Children Attending the Antiretroviral Clinic, University College Hospital, Ibadan. West Afr J Med. 2020; 37(5): 521-527.
     Google Scholar
  4. Ekouevi DK, Stringer E, Coetzee D, Tih P, Creek T, Stinson K, et al. Health facility characteristics and their relationship to coverage of PMTCT of HIV services across four African countries: the PEARL study. PLoS One. 2012; 7(1): e29823.
    DOI  |   Google Scholar
  5. Alemu FM, Yalew AW, Fantahun M, Ashu EE. Antiretroviral Therapy and Pregnancy Outcomes in Developing Countries: A Systematic Review. International Journal of MCH and AIDS. 2015; 3(1): 31–43.
    DOI  |   Google Scholar
  6. Hernandez S, Moren C, Lopez M, Coll O, Cardellach F, Gratacos E, et al. Perinatal outcomes, mitochondrial toxicity and apoptosis in HIV-treated pregnant women and in-utero-exposed newborn. Aids. 2012; 26(4): 419-428.
    DOI  |   Google Scholar
  7. Gurugubelli Krishna R, Vishnu Bhat B. Molecular mechanisms of intrauterine growth restriction. J Matern Fetal Neonatal Med. 2018; 31(19): 2634-2640.
    DOI  |   Google Scholar
  8. Hangen E, Blomgren K, Bénit P, Kroemer G, Modjtahedi N. Life with or without AIF. Trends in Biochemical Sciences. 2010; 35(5): 278-287.
    DOI  |   Google Scholar
  9. Dadhwal V, Sharma A, Khoiwal K, Deka D, Sarkar P, Vanamail P. Pregnancy Outcomes in HIV-Infected Women: Experience from a Tertiary Care Center in India. Int J MCH AIDS. 2017; 6(1): 75-81.
    DOI  |   Google Scholar
  10. Wang N, Yuan Z, Niu W, Li Q, Guo J. Synthetic biology approach for the development of conditionally replicating HIV-1 vaccine. J Chem Technol Biotechnol. 2017; 92(3): 455-462.
    DOI  |   Google Scholar
  11. Heyderman RS, Madhi SA, French N, Cutland C, Ngwira B, Kayambo D, et al. Group B streptococcus vaccination in pregnant women with or without HIV in Africa: A non-randomised phase 2, open-label, multicentre trial. The Lancet Infectious Diseases, 2016; 16(5): 546–555.
    DOI  |   Google Scholar
  12. Habib NA, Daltveit AK, Bergsjø P, Shao J, Oneko O, Lie RT. Maternal HIV Status and Pregnancy Outcomes in Northeastern Tanzania: A Registry-Based Study. BJOG: An International Journal of Obstetrics and Gynaecology. 2008; 115(5): 616–624.
    DOI  |   Google Scholar
  13. Sevrioukova IF. Apoptosis-Inducing Factor: Structure, Function, and Redox Regulation. Antioxidants & Redox Signaling. 2011.
    DOI  |   Google Scholar
  14. Guitart Mampel M, Hernandez AS, Moren C, Catalan-Garcia M, Tobias E, Gonzalez-Casacuberta I, et al. Imbalance in Mitochondrial Dynamics and Apoptosis in Pregnancies Among HIV-Infected Women on HAART with Obstetric Complications. The Journal of Antimicrobial Chemotherapy. 2017; 72(9): 2578–2586.
    DOI  |   Google Scholar
  15. Artana Putra IW, Suwiyoga K. Provision of combined antiretroviral therapy in HIV-positive pregnant women and the increased risk of apoptosis-related intra-uterine growth restriction. HIV and AIDS Review. 2019; 18(1): 1–6.
    DOI  |   Google Scholar
  16. Cossarizza A, Moyle G. Antiretroviral Nucleoside and Nucleotide Analogues and Mitochondria. Aids. 2004; 18(2): 137–151.
    DOI  |   Google Scholar


Most read articles by the same author(s)

1 2 3 4 > >>